Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer

Chang, Wenju; Ye, Wei; Li, Ren; Zhong, Yun‐Shi; Yu, Yiyi; Chen, Jingwen; Zhu, Dan; Ye, Lechi; Qin, Chunzhi; Zhao, Na; Niu, Weidong; Qin, Xinyu; Xu, Jiacheng

doi:10.1097/sla.0000000000001374

Cited by 27 publications

(28 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that peri-operative intra-portal chemotherapy combined with adjuvant chemotherapy prolonged disease-free survival after primary tumor resection and decreased liver metastasis for stage II and III colon cancer patients, without liver metastasis [39]. …”

Section: Resultsmentioning

confidence: 99%

“…Previous studies have demonstrated that 5-FU administered directly into the portal vein adjuvantly may decrease distant metastases [37, 38]. Chang, et al [39] reported that peri-operative intraportal (iPV) chemotherapy combined with adjuvant chemotherapy was useful to prolong disease-free survival after primary tumor resection and decreased liver metastasis for stage II and III colon-cancer patients without liver metastasis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High-efficacy targeting of colon-cancer liver metastasis withSalmonella typhimuriumA1-R via intra-portal-vein injection in orthotopic nude-mouse models

et al. 2016

View full text Add to dashboard Cite

Liver metastasis is the main cause of colon cancer-related death and is a recalcitrant disease. We report here the efficacy and safety of intra-portal-vein (iPV) targeting of Salmonella typhimurium A1-R on colon cancer liver metastasis in a nude-mouse orthotopic model. Nude mice with HT29 human colon cancer cells, expressing red fluorescent protein (RFP) (HT29-RFP), growing in the liver were administered S. typhimurium A1-R by either iPV (1×104 colony forming units (CFU)/100 μl) or, for comparison, intra-venous injection (iv; 5×107 CFU/100 μl). Similar amounts of bacteria were delivered to the liver with the two doses, indicating that iPV delivery is 5×103 times more efficient than iv delivery. Treatment efficacy was evaluated by tumor fluorescent area (mm2) and total fluorescence intensity. Tumor fluorescent area and fluorescence intensity highly correlated (p<0.0001). iPV treatment was more effective compared to both untreated control and iv treatment (p<0.01 and p<0.05, respectively with iPV treatment with S. typhimurium arresting metastatic growth). There were no significant differences in body weight between all groups. The results of this study suggest that S. typhimurium A1-R administered iPV has potential for peri-operative adjuvant treatment of colon cancer liver metastasis.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

High-efficacy targeting of colon-cancer liver metastasis withSalmonella typhimuriumA1-R via intra-portal-vein injection in orthotopic nude-mouse models

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In 2002, only in Europe, >370,000 people suffered from it, and ~200,000 people succumbed to the disease, which accounted for 12% of all cancer mortalities (2). In China, at present, colon cancer is ranked as the fifth most common tumor, whose growth speed is very fast, particularly in certain large cities (3). However, colon cancer's lack of specificity in terms of clinical symptoms leads to patients being often misdiagnosed, thus delaying treatment (4).…”

Section: Introductionmentioning

confidence: 99%

Anticancer effect of icaritin inhibits cell growth of colon cancer through reactive oxygen species, Bcl-2 and cyclin D1/E signaling

Peng

Song

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Icaritin has an advantage in enhancing immunity. Besides, with its anticancer effect, it may be of great help in cancer treatment and recovery of cancer patients. As a result, icaritin is likely to become a novel anticancer drug. However, the anticancer effect of icaritin against colon cancer has not been elucidated thus far. The present study investigated the latent anticancer effect of icaritin on the inhibition of colon cancer cell growth by regulating reactive oxygen species (ROS), B-cell lymphoma (Bcl)-2 and cyclin D1/E signaling. The COLO-205 colon cancer cell line was used as a colon cancer cell model in the present study. First, cell growth and apoptosis were measured to analyze the anticancer effect of icaritin against colon cancer. Next, the possible mechanism of icaritin against colon cancer, including ROS, Bcl-2, cyclin D1, cyclin E and caspase-3/9, was explored. The results revealed that icaritin could inhibit cell growth and induce the apoptosis of COLO-205 cells. In addition, icaritin significantly induced ROS generation, suppressed Bcl-2, cyclin D1 and cyclin E protein expression, and activated caspase-3/9 activity in COLO-205 cells. The present findings demonstrated that icaritin exerted antiproliferative and anticancer effects against colon cancer through the activation of ROS generation and the suppression of Bcl-2, cyclin D1 and cyclin E signaling.

show abstract

“…Adding oxaliplatin to FU has resulted in an approximate 20% relative risk reduction for disease-free survival. At present, the first line treatment of colorectal cancer includes mFOLFOX6 with or without targeted drugs bevacizumab or cetuximab [2, 3]. The mFOLFOX6 regimen contains leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.…”

Section: Introductionmentioning

confidence: 99%

The role of GLI1 for 5-Fu resistance in colorectal cancer

Zhang

Song

et al. 2017

Cell Biosci

View full text Add to dashboard Cite

Colorectal cancer is a leading cause of cancer-related mortality worldwide, with Fluorouracil (5-FU)-based chemotherapy as the major treatment for advanced disease. Many patients with advanced colorectal cancer eventually succumb to the disease despite some patients responded initially to chemotherapy. Thus, identifying molecular mechanisms responsible for chemotherapy resistance will help design novel strategies to treat colorectal cancer. In this study, we established an acquired 5-FU resistant cell line, LoVo-R, from LoVo cells. Through exome sequencing, we discovered that elevated GLI1 signaling axis is a major genetic alteration in the 5-FU resistant cells. Hh signaling, a pathway essential for embryonic development, is an important regulator for residual cancer cells. We demonstrated that knockdown of GLI1 or GLI2 sensitized LoVo-R cells to 5-FU treatment, reduced cell invasiveness. The relevance of our studies to colorectal cancer patients is reflected by our discovery that high expression of GLI1 signaling molecules was associated with a high incidence of cancer relapse and a shorter survival in a larger cohort of colorectal cancer patients who underwent chemotherapy (containing 5-FU). Taken together, our data demonstrate the critical role of the GLI1 signaling axis for 5-FU resistance in colorectal cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/s13578-017-0145-7) contains supplementary material, which is available to authorized users.

show abstract

Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer

Abstract: Combination of intraoperative intraportal chemotherapy with mFOLFOX6 reduced the occurrence of distant metastases and improved disease-free survival in patients with stage II and stage III colon cancer.

Cited by 27 publications

References 28 publications

High-efficacy targeting of colon-cancer liver metastasis withSalmonella typhimuriumA1-R via intra-portal-vein injection in orthotopic nude-mouse models

High-efficacy targeting of colon-cancer liver metastasis withSalmonella typhimuriumA1-R via intra-portal-vein injection in orthotopic nude-mouse models

Anticancer effect of icaritin inhibits cell growth of colon cancer through reactive oxygen species, Bcl-2 and cyclin D1/E signaling

The role of GLI1 for 5-Fu resistance in colorectal cancer

Contact Info

Product

Resources

About